Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

Libtayo (cemiplimab). The company's stock has shown remarkable resilience, posting a 54% gain over the past six months, according to InvestingPro data. This collaboration will focus on patients ...

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more ...

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can ...

Announced Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) : In February, Immuneering announced a clinical trial supply ...

These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab. Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 ...

In PD-(L)1 resistant hot tumors, solnerstotug+cemiplimab showed 14% ORR, nearly 3x higher than historical PD-(L)1 rechallenge response rates Solnerstotug remains well tolerated, with no dose ...

The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination with Libtayo, Regeneron’s PD-1 inhibitor ...